VAPILIR atorvastatin (as calcium) 20 mg film-coated tablet blister pack

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

atorvastatin calcium, Quantity: 20.68 mg (Equivalent: atorvastatin, Qty 20 mg)

Disponible des:

Medis Pharma Pty Ltd

Designació comuna internacional (DCI):

Atorvastatin calcium

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: colloidal anhydrous silica; microcrystalline cellulose; hyprolose; pregelatinised maize starch; magnesium stearate; activated attapulgite; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000

Vía de administración:

Oral

Unidades en paquete:

50, 40, 30, 10, 20

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

As an adjunct to diet for the treatment of patients with hypercholesterolaemia. Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,Indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD (see CLINICAL TRIALS, Prevention of Cardiovascular Disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Resumen del producto:

Visual Identification: White, oval bi-convex tablets with breakline on one side; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Estat d'Autorització:

Licence status A

Data d'autorització:

2011-09-16